Fair and cost-conscious allocation of omalizumab, a groundbreaking food allergy therapy

Ann Allergy Asthma Immunol. 2024 Jul;133(1):18-19. doi: 10.1016/j.anai.2024.04.020.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anti-Allergic Agents* / economics
  • Anti-Allergic Agents* / therapeutic use
  • Cost-Benefit Analysis
  • Food Hypersensitivity* / drug therapy
  • Food Hypersensitivity* / economics
  • Humans
  • Omalizumab* / therapeutic use

Substances

  • Omalizumab
  • Anti-Allergic Agents